- The stock price of Precigen Inc (NASDAQ: PGEN) increased by over 14% during intraday trading today. This is why.
The stock price of Precigen Inc (NASDAQ: PGEN) – a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients – increased by over 14% during intraday trading today. Investors are responding positively to the company announcing that the company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary Trans Ova Genetics L.C., an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out based on the performance of Trans Ova in 2022 and 2023.
Rabo Securities USA is acting as exclusive financial advisor to Precigen and Davis Polk & Wardwell LLP is providing Precigen with legal support for the transaction.
“We believe this transaction will support Precigen’s mission as a premier cell and gene therapy company laser-focused on the rapid development of our top clinical assets to maximize shareholder value and potentially improve the way devastating diseases like cancer are treated. I am proud of Precigen management and the Trans Ova team for successfully leading the financial turnaround of Trans Ova operations to maximize the value of this asset over the last two years. We expect to have the capacity to pay the convertible notes upon maturity and to focus on fast regulatory paths for our healthcare portfolio.”
— Helen Sabzevari, PhD, President and CEO of Precigen
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.